Alx Other Stockholder Equity vs Net Receivables Analysis

ALXO Stock

USD 10.63 0.02 0.19%

Alx Oncology financial indicator trend analysis is way more than just evaluating Alx Oncology Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alx Oncology Holdings is a good investment. Please check the relationship between Alx Oncology Other Stockholder Equity and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

Other Stockholder Equity vs Net Receivables

Other Stockholder Equity vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alx Oncology Holdings Other Stockholder Equity account and Net Receivables. At this time, the significance of the direction appears to have weak relationship.

The correlation between Alx Oncology's Other Stockholder Equity and Net Receivables is 0.39. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Alx Oncology Holdings, assuming nothing else is changed. The correlation between historical values of Alx Oncology's Other Stockholder Equity and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Alx Oncology Holdings are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Other Stockholder Equity i.e., Alx Oncology's Other Stockholder Equity and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.39

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Other Stockholder Equity

Net Receivables

Most indicators from Alx Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alx Oncology Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

At this time, Alx Oncology's Issuance Of Capital Stock is very stable compared to the past year. As of the 31st of May 2024, Sales General And Administrative To Revenue is likely to grow to 11.84, while Tax Provision is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	83.6M	127.4M	169.4M	177.9M
Cost Of Revenue	736K	1.5M	836K	1.4M

Total Operating Expenses Cost Of Revenue

Alx Oncology fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.54	0.65	-0.38	0.33	0.99	0.53	-0.85	-0.65	0.51	0.87	0.55	1.0	0.45	0.95	0.86	0.48	0.94	0.74	0.41	0.68	1.0	0.53	1.0	-0.96	0.99
Other Current Liab	0.54		0.96	0.25	-0.26	0.58	0.96	-0.07	-0.96	0.8	0.11	0.97	0.49	0.43	0.7	0.71	0.96	0.7	0.8	0.87	0.2	0.53	0.96	0.48	-0.74	0.44
Total Current Liabilities	0.65	0.96		0.13	0.03	0.68	0.98	-0.19	-1.0	0.88	0.23	0.99	0.59	0.42	0.79	0.81	0.96	0.8	0.89	0.83	0.13	0.63	0.98	0.59	-0.82	0.54
Total Stockholder Equity	-0.38	0.25	0.13		-0.38	-0.31	0.14	0.74	-0.19	-0.08	-0.72	0.25	-0.42	0.01	-0.27	-0.17	0.19	-0.27	-0.19	0.62	-0.18	-0.39	0.17	-0.41	0.22	-0.42
Other Liab	0.33	-0.26	0.03	-0.38		0.3	-0.06	-0.43	-0.01	0.12	0.42	-0.07	0.34	-0.11	0.26	0.3	-0.12	0.25	0.15	-0.19	-0.16	0.33	-0.07	0.34	-0.22	0.35
Net Tangible Assets	0.99	0.58	0.68	-0.31	0.3		0.56	-0.81	-0.69	0.56	0.83	0.59	0.98	0.52	0.97	0.87	0.51	0.97	0.78	0.47	0.66	0.99	0.56	0.98	-0.97	0.97
Property Plant And Equipment Net	0.53	0.96	0.98	0.14	-0.06	0.56		-0.08	-0.97	0.89	0.12	0.99	0.47	0.43	0.7	0.71	0.97	0.71	0.88	0.79	0.0	0.51	1.0	0.47	-0.74	0.42
Net Debt	-0.85	-0.07	-0.19	0.74	-0.43	-0.81	-0.08		0.18	-0.17	-1.0	-0.07	-0.89	-0.27	-0.7	-0.59	-0.03	-0.7	-0.43	0.12	-0.69	-0.86	-0.06	-0.88	0.69	-0.9
Retained Earnings	-0.65	-0.96	-1.0	-0.19	-0.01	-0.69	-0.97	0.18		-0.87	-0.22	-0.99	-0.59	-0.46	-0.8	-0.8	-0.95	-0.8	-0.89	-0.87	-0.16	-0.63	-0.98	-0.59	0.83	-0.54
Accounts Payable	0.51	0.8	0.88	-0.08	0.12	0.56	0.89	-0.17	-0.87		0.21	0.85	0.45	0.24	0.72	0.78	0.91	0.74	0.88	0.58	-0.06	0.5	0.88	0.44	-0.67	0.39
Cash	0.87	0.11	0.23	-0.72	0.42	0.83	0.12	-1.0	-0.22	0.21		0.11	0.9	0.28	0.73	0.62	0.07	0.72	0.46	-0.08	0.69	0.88	0.1	0.9	-0.71	0.91
Non Current Assets Total	0.55	0.97	0.99	0.25	-0.07	0.59	0.99	-0.07	-0.99	0.85	0.11		0.49	0.44	0.72	0.73	0.96	0.72	0.85	0.88	0.07	0.53	0.99	0.49	-0.76	0.44
Cash And Short Term Investments	1.0	0.49	0.59	-0.42	0.34	0.98	0.47	-0.89	-0.59	0.45	0.9	0.49		0.41	0.92	0.84	0.42	0.91	0.69	0.35	0.7	1.0	0.46	1.0	-0.93	1.0
Net Receivables	0.45	0.43	0.42	0.01	-0.11	0.52	0.43	-0.27	-0.46	0.24	0.28	0.44	0.41		0.54	0.16	0.23	0.55	0.63	0.39	0.21	0.46	0.43	0.42	-0.56	0.4
Common Stock Total Equity	0.95	0.7	0.79	-0.27	0.26	0.97	0.7	-0.7	-0.8	0.72	0.73	0.72	0.92	0.54		0.9	0.65	1.0	0.9	0.54	0.52	0.94	0.7	0.92	-0.98	0.89
Common Stock Shares Outstanding	0.86	0.71	0.81	-0.17	0.3	0.87	0.71	-0.59	-0.8	0.78	0.62	0.73	0.84	0.16	0.9		0.75	0.9	0.77	0.59	0.47	0.85	0.71	0.84	-0.88	0.81
Non Current Liabilities Total	0.48	0.96	0.96	0.19	-0.12	0.51	0.97	-0.03	-0.95	0.91	0.07	0.96	0.42	0.23	0.65	0.75		0.66	0.79	0.8	0.04	0.46	0.97	0.42	-0.67	0.37
Capital Surpluse	0.94	0.7	0.8	-0.27	0.25	0.97	0.71	-0.7	-0.8	0.74	0.72	0.72	0.91	0.55	1.0	0.9	0.66		0.91	0.55	0.51	0.94	0.71	0.91	-0.97	0.88
Other Current Assets	0.74	0.8	0.89	-0.19	0.15	0.78	0.88	-0.43	-0.89	0.88	0.46	0.85	0.69	0.63	0.9	0.77	0.79	0.91		0.58	0.16	0.73	0.87	0.68	-0.88	0.64
Other Stockholder Equity	0.41	0.87	0.83	0.62	-0.19	0.47	0.79	0.12	-0.87	0.58	-0.08	0.88	0.35	0.39	0.54	0.59	0.8	0.55	0.58		0.2	0.39	0.81	0.36	-0.6	0.32
Total Liab	0.68	0.2	0.13	-0.18	-0.16	0.66	0.0	-0.69	-0.16	-0.06	0.69	0.07	0.7	0.21	0.52	0.47	0.04	0.51	0.16	0.2		0.68	0.01	0.71	-0.53	0.73
Net Invested Capital	1.0	0.53	0.63	-0.39	0.33	0.99	0.51	-0.86	-0.63	0.5	0.88	0.53	1.0	0.46	0.94	0.85	0.46	0.94	0.73	0.39	0.68		0.51	1.0	-0.95	0.99
Property Plant And Equipment Gross	0.53	0.96	0.98	0.17	-0.07	0.56	1.0	-0.06	-0.98	0.88	0.1	0.99	0.46	0.43	0.7	0.71	0.97	0.71	0.87	0.81	0.01	0.51		0.46	-0.74	0.41
Total Current Assets	1.0	0.48	0.59	-0.41	0.34	0.98	0.47	-0.88	-0.59	0.44	0.9	0.49	1.0	0.42	0.92	0.84	0.42	0.91	0.68	0.36	0.71	1.0	0.46		-0.93	1.0
Capital Stock	-0.96	-0.74	-0.82	0.22	-0.22	-0.97	-0.74	0.69	0.83	-0.67	-0.71	-0.76	-0.93	-0.56	-0.98	-0.88	-0.67	-0.97	-0.88	-0.6	-0.53	-0.95	-0.74	-0.93		-0.91
Net Working Capital	0.99	0.44	0.54	-0.42	0.35	0.97	0.42	-0.9	-0.54	0.39	0.91	0.44	1.0	0.4	0.89	0.81	0.37	0.88	0.64	0.32	0.73	0.99	0.41	1.0	-0.91

Click cells to compare fundamentals

Alx Oncology Account Relationship Matchups

Alx Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.7M	436.1M	380.2M	306.5M	242.6M	254.3M
Other Current Liab	1.2M	6.2M	257K	19.2M	25.8M	27.1M
Total Current Liabilities	5.0M	6.2M	15.3M	28.3M	36.0M	37.8M
Total Stockholder Equity	(276K)	(118.5M)	(202.0M)	(325.5M)	189.7M	199.2M
Other Liab	547K	5K	1.8M	53K	61.0K	57.9K
Net Tangible Assets	(70.6M)	429.8M	363.0M	263.5M	303.0M	205.5M
Property Plant And Equipment Net	860K	52K	3.5M	9.8M	10.8M	11.4M
Net Debt	(3.6M)	(434.2M)	(362.9M)	(272.5M)	(5.2M)	(5.5M)
Retained Earnings	(72.8M)	(118.5M)	(202.0M)	(325.5M)	(486.3M)	(462.0M)
Accounts Payable	3.7M	4K	3.8M	8.1M	8.6M	4.6M
Cash	9.0M	434.2M	363.7M	282.9M	22.4M	21.3M
Non Current Assets Total	867K	1.8M	13.2M	35.5M	53.9M	56.6M
Cash And Short Term Investments	9.0M	434.2M	363.7M	282.9M	182.7M	234.8M
Common Stock Shares Outstanding	36.5M	39.8M	40.3M	40.7M	43.0M	40.8M
Liabilities And Stockholders Equity	10.7M	436.1M	(184.9M)	(282.4M)	242.6M	254.7M
Non Current Liabilities Total	6.0M	5K	1.8M	14.7M	16.8M	17.7M
Capital Surpluse	2.1M	548.3M	565.0M	589.7M	678.2M	375.5M
Other Current Assets	256K	1.8M	3.4M	4.8M	4.9M	2.9M
Other Stockholder Equity	2.1M	118.5M	(41K)	804K	675.7M	709.5M
Total Liab	11.0M	436.1M	17.1M	43.0M	52.8M	74.9M
Net Invested Capital	(65.2M)	429.8M	363.0M	272.9M	199.4M	210.5M
Property Plant And Equipment Gross	860K	52K	3.5M	10.2M	12.1M	12.7M
Total Current Assets	9.8M	434.2M	367.0M	271.0M	188.7M	234.8M
Accumulated Other Comprehensive Income	(1.4M)	(554.6M)	0.0	(845K)	256K	268.8K
Net Working Capital	4.8M	429.8M	351.7M	242.6M	152.7M	218.2M
Property Plant Equipment	860K	52K	897K	3.9M	4.5M	4.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock:

How To Invest In Alx

Details

Is Alx Stock a good investment?

Details

What is Alx Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Alx Stock analysis

When running Alx Oncology's price analysis, check to measure Alx Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alx Oncology is operating at the current time. Most of Alx Oncology's value examination focuses on studying past and present price action to predict the probability of Alx Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alx Oncology's price. Additionally, you may evaluate how the addition of Alx Oncology to your portfolios can decrease your overall portfolio volatility.

	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Technical Analysis Check basic technical indicators and analysis based on most latest market data

Is Alx Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.54)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.45)

Return On Equity

(0.82)

The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alx Other Stockholder Equity vs Net Receivables Analysis

Other Stockholder Equity vs Net Receivables

Other Stockholder Equity vs Net Receivables Correlation Analysis

Correlation Coefficient

Other Stockholder Equity

Net Receivables

Alx Oncology fundamental ratios Correlations

Alx Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alx Oncology fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Alx Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Net Invested Capital	+ 1.0	Cash And Short Term Investments
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Retained Earnings	- 1.0	Total Current Liabilities
Non Current Assets Total	- 0.99	Retained Earnings
Capital Stock	- 0.98	Common Stock Total Equity
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Capital Stock	- 0.97	Capital Surpluse